Ryan Vander Werff
Impact in
-
- Renal and related cancers
- Pluripotent Stem Cells Research
- CRISPR and Genetic Engineering
-
- Renal cell carcinoma treatment
Papers in
-
- Pluripotent Stem Cells Research 2
- Epigenetics and DNA Methylation 1
- RNA modifications and cancer 1
- Protein Degradation and Inhibitors 1
- Histone Deacetylase Inhibitors Research 1
-
- Sarcoma Diagnosis and Treatment 1
- Renal cell carcinoma treatment 1
- Co-authors
- Kelly M. McNagny (3 shared papers)Hongxia Fu (1 shared paper)Junjie Lu (1 shared paper)Joseph V. Bonventre (1 shared paper)Theodore I. Steinman (1 shared paper)Derek Peters (1 shared paper)M. Todd Valerius (1 shared paper)Craig R. Brooks (1 shared paper)
- Journals
- Nature Communications (1 paper)Science Translational Medicine (1 paper)SpringerPlus (1 paper)Development (1 paper)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- CanadaUnited StatesJapan
In The Last Decade
Ryan Vander Werff
7 papers receiving 768 citations
Ryan Vander Werff's Hit Papers
Peers
Comparison fields: 5 of 67
- Molecular Biology 580
- Pulmonary and Respiratory Medicine 171
- Aging 10
- Nephrology 37
- Developmental Neuroscience 19
Countries citing papers authored by Ryan Vander Werff
This map shows the geographic impact of Ryan Vander Werff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan Vander Werff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan Vander Werff more than expected).
Fields of papers citing papers by Ryan Vander Werff
This network shows the impact of papers produced by Ryan Vander Werff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan Vander Werff. The network helps show where Ryan Vander Werff may publish in the future.
Co-authors
The 25 scholars most cited alongside Ryan Vander Werff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids Hit paper breakdown → | 2015 | 578 |
| 2 | 2017 | 77 | |
| 3 | 2015 | 53 | |
| 4 | 2021 | 34 | |
| 5 | 2017 | 27 | |
| 6 | 2015 | 2 | |
| 7 | 2020 | 1 |
About Ryan Vander Werff
Ryan Vander Werff is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Genetics, Cardiology and Cardiovascular Medicine and Oncology, having authored 7 papers that have together received 772 indexed citations. Recurring topics across this work include Pluripotent Stem Cells Research (2 papers), Sarcoma Diagnosis and Treatment (1 paper), Neurogenesis and neuroplasticity mechanisms (1 paper), Epigenetics and DNA Methylation (1 paper), Renal cell carcinoma treatment (1 paper), RNA modifications and cancer (1 paper), Protein Degradation and Inhibitors (1 paper) and Histone Deacetylase Inhibitors Research (1 paper). The work is most often cited by research in Molecular Biology (580 citations), Pulmonary and Respiratory Medicine (171 citations), Aging (10 citations), Nephrology (37 citations) and Developmental Neuroscience (19 citations). Ryan Vander Werff has collaborated with scholars based in Canada, United States and Japan. Frequent co-authors include Kelly M. McNagny, Hongxia Fu, Junjie Lu, Joseph V. Bonventre, Theodore I. Steinman, Derek Peters, M. Todd Valerius, Craig R. Brooks, Anna Baccei and Benjamin Freedman. Their work appears in journals such as Nature Communications, Science Translational Medicine, SpringerPlus, Development and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.